Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, in association with the John Black Charitable Foundation, is pleased to welcome Dr Ira Milosevic as a John Black Senior Research Fellow in Parkinson’s Disease Research.

Ira Milosevic

The John Black Senior Research Fellowship aims to build on the strengths of the University's Central Nervous System (CNS) research programmes and world leading research into the discovery and translation of novel therapeutic approaches for neurodegenerative diseases, with a particular focus on Parkinson's disease. As a principal investigator, Dr Milosevic will provide strategic and academic leadership, pioneering studies and development of worldwide scientific collaborations.

"My colleagues and I are delighted to be welcoming Dr Milosevic to the University of Oxford and Nuffield Department of Medicine", says Dr Davis, CSO of the ARUK Oxford Drug Discovery Institute (ODDI), "Disturbances in the normal function of subcellular organelles has been highlighted as a possible cause of several neurodegenerative diseases and Ira's expertise in the field will provide a major boost to expansion of our understanding of the functional genetics of Parkinson's disease, in particular".

Dr Milosevic, who joins the University from the European Neuroscience Institute – Göttingen, said: "I am honoured to accept the John Black Senior Research Fellowship and excited to be joining the University of Oxford. I am extremely grateful to the John Black Charitable Foundation for providing financial support and for their efforts to promote translational research in Parkinson's disease. I look forward to helping advance their important mission and to collaborating with the exceptional faculty and students at the Nuffield Department of Medicine and Wellcome Centre for Human Genetics. "

About the John Black Charitable Foundation

John Black Charitable Foundation (JBCF) was created out of the Will of the Late John Black. The aim of JBCF is to promote quality research in the areas of Parkinson's disease and Prostate Cancer. Since its inception, JBCF has committed substantial funding for a large number of research projects at many of the UK's leading institutions.

Similar stories

PRINCIPLE Covid-19 treatments trial widens to under 50s and adds colchicine

Clinical Trials Coronavirus COVID-19 General Research

From today, the UK’s national priority platform trial of Covid-19 treatments for recovery at home launches its investigation of the gout drug colchicine, and expands for the first time to include adults of any age.

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.